Predicate Devices

Not Applicable. This is a De Novo submission.

Reference Devices

P120005, P120005/S033

AI/ML (Artificial Intelligence / Machine Learning)

No
The summary does not mention AI, ML, or related terms, and the description of the device and studies focuses on traditional statistical performance metrics and clinical trial methodology.

Therapeutic

No.
This device measures glucose levels and provides alerts, aiding in diabetes management and facilitating therapy adjustments. However, it does not directly administer treatment or physically alter the body to treat the disease; it provides information for treatment decisions.

Diagnostic

Yes
The device is intended for the "management of diabetes" and "aids in the detection of episodes of hyperglycemia and hypoglycemia," which are diagnostic functions. It also provides "glucose levels, trends, and alerts" to "warn the user of low or impending low and high or impending high glucose levels."

SaMD (Software as a Medical Device)

No

The device description explicitly states the system consists of three main components: a sensor, a Bluetooth Low Energy (BLE) transmitter, and a BLE enabled display device (receiver and/or mobile application). This includes hardware components (sensor and transmitter) in addition to the software (mobile application).

IVD (In Vitro Diagnostic)

Based on the provided information, the Dexcom G6 Continuous Glucose Monitoring System is an In Vitro Diagnostic (IVD) device.

Here's why:

Intended Use: The primary intended use is for the management of diabetes by measuring glucose levels. This involves analyzing a biological sample (interstitial fluid, which is closely related to blood glucose).
Replacement of Fingerstick Blood Glucose Testing: The system is intended to replace traditional fingerstick blood glucose testing, which is a classic IVD method.
Aiding in Detection of Hyperglycemia and Hypoglycemia: The system provides data used to diagnose and monitor these conditions, which falls under the scope of IVD.
Analysis of Biological Samples: While the description doesn't explicitly state "blood," continuous glucose monitoring systems like the Dexcom G6 measure glucose in the interstitial fluid, which is a biological sample.

The definition of an IVD device generally includes devices intended for use in vitro for the examination of specimens derived from the human body to provide information for diagnostic, monitoring, or compatibility purposes. The Dexcom G6 fits this description by analyzing interstitial fluid to provide information for the management and monitoring of diabetes.

PCCP (Predetermined Change Control Plan) Authorized

N/A

Overview

Intended Use / Indications for Use

The Dexcom G6 Continuous Glucose Monitoring System (Dexcom G6 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons age 2 years and older.

The Dexcom G6 System is intended to replace fingerstick blood glucose testing for diabetes treatment decisions. Interpretation of the Dexcom G6 System results should be based on the glucose trends and several sequential readings over time. The Dexcom G6 System also aids in the detection of episodes of hyperglycemia and hypoglycemia, facilitating both acute and long-term therapy adjustments.

The Dexcom G6 System is also intended to autonomously communicate with digitally connected devices, including automated insulin dosing (AID) systems. The Dexcom G6 System can be used alone or in conjunction with these digitally connected medical devices for the purpose of managing diabetes.

Product codes (comma separated list FDA assigned to the subject device)

OBJ, QBJ

Device Description

The Dexcom G6 System in an integrated continuous glucose monitoring system (iCGM) that provides continuous glucose readings which are updated every 5 minutes providing glucose levels, trends, and alerts. The System consists of three main components: a sensor, a Bluetooth Low Energy (BLE) transmitter and a BLE enabled display device (receiver and/or mobile application). The user can view glucose data on the receiver or on the G6 CGM App (i.e., a mobile medical application) running on a compatible mobile device, or on both simultaneously.

The system provides alerts and alarms which warn the user of low or impending low and high or impending high glucose levels. The user may determine their treatment based on the glucose values provided by the system.

G6 CGM SENSOR
The sensor component is a sterile device that consists of the sensor applicator, plastic base ("transmitter holder"), and sensor probe. The applicator is a single use, disposable unit that contains an introducer needle holding the sensor probe. The applicator deploys the needle and inserts the sensor under the skin. The needle is retracted back into the applicator after insertion. The sensor probe continuously measures glucose concentration in interstitial fluid and can be worn for up to 10 days.

The sensor may be worn in the abdomen for adults, and both the abdomen and buttock for children ages 2-17 years old. Sensor comes with a calibration code that the user enters into the system upon initializing a new sensor. Once the code is applied, the user does not need to calibrate the system throughout the entirety of the sensor lifetime, which is 10 days. However, the user has the option to manually calibrate the system using self-measurements from a blood glucose meter in addition to entering the calibration code. Alternatively, if the user chooses not to enter the calibration code, he or she must manually calibrate the sensor by entering two fingerstick blood glucose values during start up and every 24 hours thereafter.

G6 CGM TRANSMITTER
The G6 CGM Transmitter is a miniature radio transmitter that incorporates data processing functionality. The transmitter contains a Bluetooth radio transceiver for communication with a compatible display device (i.e., receiver and/or smart device). The transmitter attaches to the sensor and can be re-used for multiple sensing sessions up to three months.

G6 CGM RECEIVER
The G6 CGM Receiver is small hand-held device that wirelessly receives glucose information from the transmitter every five minutes and includes a touchscreen display. The receiver displays the current glucose reading and glucose trends to the user. It alerts the user when glucose levels are outside of a target zone and when other important system conditions occur.

DEXCOM G6 System MOBILE APP
The G6 CGM App for iOS and G6 CGM App for Android provides an alternative display device to the receiver for users with a compatible, BLE-enabled smart device and behaves similarly to the receiver. The G6 CGM App is compatible with certain iOS, Android and Smart Device watches. A link to a list of compatible devices is included in the instructions for use.

The Dexcom G6 System is an interoperable connected device that can communicate glucose readings and other information wirelessly and securely to and from interoperable electronic interfaces; including compatible AID systems. The G6 CGM system is designed to communicate with interoperable devices in several ways, such as described below:

· Wireless communication from the transmitter directly to an interoperable device communicating through the same protocol.
· The app communicates to another app on a single mobile platform.
· The app communicates through the cloud to another software device.

Mentions image processing

Not Found

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Not Found

Anatomical Site

Abdomen, Buttock

Indicated Patient Age Range

2 years and older

Intended User / Care Setting

Not Found

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)

Two clinical studies were conducted to support the accuracy performance of the device: Study 1 (Effectiveness and Safety of the Dexcom G6 Continuous Glucose Monitoring System) and Study 2 (Effectiveness and Safety of the Dexcom G6 Continuous Glucose Monitoring System with an Automated Applicator).

Studies included 380 total participants (adults 18+ and pediatrics 2-17 years), with 324 completing the studies. 99% had Type 1 diabetes, 1% insulin-using Type 2 diabetes. Participants wore one or two sensors for up to 10 days. Adult participants wore sensors on the abdomen only; pediatric subjects on either abdomen or upper buttocks. Clinic sessions occurred on Day 1, Day 4-5, Day 7, and/or Day 10.

In Study 1, participants 13 years and older had their glucose levels deliberately manipulated (40-400 mg/dl) to assess performance. In Study 2, participants managed their glucose normally without deliberate manipulation.

Accuracy was evaluated by comparing iCGM values to comparator methods (laboratory blood glucose comparator method for most, blood glucose meter for pediatrics 2-5 years). Absolute differences were calculated for values =70 mg/dL.

Key results from accuracy tables:

Adults (N=159)

180 mg/dL: 85.5% within 15%, 99.9% within 40%. Mean Bias: -7.0 mg/dL.
Overall (40-400 mg/dL): 89.5% within 20%.

Pediatrics (N=165)

180 mg/dL: 85.8% within 15%, 99.9% within 40%. Mean Bias: 2.9 mg/dL.
Overall (40-400 mg/dL): 91.0% within 20% (6-17 years old), 92.7% within 20% (2-5 years old).

Sensor Stability Relative to Comparator (Accuracy Over Time):

Beginning: MARD 10.7%, 77.6% within 15/15%, 89.0% within 20/20%, 99.6% within 40/40%.
Middle: MARD 9.2%, 84.1% within 15/15%, 94.4% within 20/20%, 99.8% within 40/40%.
End: MARD 9.6%, 82.6% within 15/15%, 92.0% within 20/20%, 99.5% within 40/40%.

Sensor Life: 84% of sensors lasted through the 10-day wear period.
Reading Capture Rate: 98.6% of readings received over the sensor life.

Analytical Performance (Precision):

67 subjects wore two devices concurrently. Mean absolute relative difference (between 2 concurrently worn devices) was 9.6%; mean coefficient of variation (CV) was 8.4%.
Adults (18+ YO) - Abdomen: Paired Absolute Relative Difference 8.9% with CV of 7.9%.
Pediatrics (2-5 YO) - Upper Buttocks: Paired ARD 5.2% with CV of 4.8%.

Analytical Performance (Acetaminophen Interference):

A clinical study with 70 subjects (4 sites) evaluated acetaminophen interference. Subjects wore G6 and G4 CGM. A single 1000 mg dose of acetaminophen was given.
Study data indicates that a single dose of 1000 mg does not introduce significant interference to the device.
Mean absolute relative difference (MARD) increased 1% (7% pre-dose vs. 8% post-dose).
Mean MIE of C6 sensor was 5.2 mg/dL, statistically significantly lower than 10 mg/dL goal (one-sided upper 95% CI of 6.4 mg/dL, p 180 mg/dL): 85.5% (95%LB 82.8)
- Percent Within 40% (>180 mg/dL): 99.9% (95%LB 99.9)
- Percent within 20% (Overall 40-400 mg/dL): 89.9% (95%LB 88.7)
Pediatrics (N=165)
- Percent Within 15 mg/dL (180 mg/dL): 85.8% (95%LB 81.7)
- Percent Within 40% (>180 mg/dL): 99.9% (95%LB 99.8)
- Percent within 20% (Overall 40-400 mg/dL): 91.0% (95%LB 88.7)

Mean Absolute Relative Difference (MARD):

Adults, 250 mg/dL: 7.1%
Pediatrics, 250 mg/dL: 7.4% (Abdomen 7.5%, Buttocks 7.3%)

Agreement when iCGM Reads "LOW" or "HIGH":

"LOW" (n=139 pairs): Cumulative % =80: 16%.
"HIGH" (n=54 pairs): Cumulative % >340: 53, >320: 53, >280: 54, >250: 54,

Regulation Number and Section

§ 862.1355 Integrated continuous glucose monitoring system.

(a)
Identification. An integrated continuous glucose monitoring system (iCGM) is intended to automatically measure glucose in bodily fluids continuously or frequently for a specified period of time. iCGM systems are designed to reliably and securely transmit glucose measurement data to digitally connected devices, including automated insulin dosing systems, and are intended to be used alone or in conjunction with these digitally connected medical devices for the purpose of managing a disease or condition related to glycemic control.(b)
Classification. Class II (special controls). The special controls for this device are:(1) Design verification and validation must include the following:
(i) Robust clinical data demonstrating the accuracy of the device in the intended use population.
(ii) The clinical data must include a comparison between iCGM values and blood glucose values in specimens collected in parallel that are measured on an FDA-accepted laboratory-based glucose measurement method that is precise and accurate, and that is traceable to a higher order (
e.g., an internationally recognized reference material and/or method).(iii) The clinical data must be obtained from a clinical study designed to fully represent the performance of the device throughout the intended use population and throughout the measuring range of the device.
(iv) Clinical study results must demonstrate consistent analytical and clinical performance throughout the sensor wear period.
(v) Clinical study results in the adult population must meet the following performance requirements:
(A) For all iCGM measurements less than 70 milligrams/deciliter (mg/dL), the percentage of iCGM measurements within ±15 mg/dL of the corresponding blood glucose value must be calculated, and the lower one-sided 95 percent confidence bound must exceed 85 percent.
(B) For all iCGM measurements from 70 mg/dL to 180 mg/dL, the percentage of iCGM measurements within ±15 percent of the corresponding blood glucose value must be calculated, and the lower one-sided 95 percent confidence bound must exceed 70 percent.
(C) For all iCGM measurements greater than 180 mg/dL, the percentage of iCGM measurements within ±15 percent of the corresponding blood glucose value must be calculated, and the lower one-sided 95 percent confidence bound must exceed 80 percent.
(D) For all iCGM measurements less than 70 mg/dL, the percentage of iCGM measurements within ±40 mg/dL of the corresponding blood glucose value must be calculated, and the lower one-sided 95 percent confidence bound must exceed 98 percent.
(E) For all iCGM measurements from 70 mg/dL to 180 mg/dL, the percentage of iCGM measurements within ±40 percent of the corresponding blood glucose value must be calculated, and the lower one-sided 95 percent confidence bound must exceed 99 percent.
(F) For all iCGM measurements greater than180 mg/dL, the percentage of iCGM measurements within ±40 percent of the corresponding blood glucose value must be calculated, and the lower one-sided 95 percent confidence bound must exceed 99 percent.
(G) Throughout the device measuring range, the percentage of iCGM measurements within ±20 percent of the corresponding blood glucose value must be calculated, and the lower one-sided 95 percent confidence bound must exceed 87 percent.
(H) When iCGM values are less than 70 mg/dL, no corresponding blood glucose value shall read above 180 mg/dL.
(I) When iCGM values are greater than 180 mg/dL, no corresponding blood glucose value shall read less than 70 mg/dL.
(J) There shall be no more than 1 percent of iCGM measurements that indicate a positive glucose rate of change greater than 1 mg/dL per minute (/min) when the corresponding true negative glucose rate of change is less than −2 mg/dL/min as determined by the corresponding blood glucose measurements.
(K) There shall be no more than 1 percent of iCGM measurements that indicate a negative glucose rate of change less than −1 mg/dL/min when the corresponding true positive glucose rate of change is greater than 2 mg/dL/min as determined by the corresponding blood glucose measurements.
(vi) Data demonstrating similar accuracy and rate of change performance of the iCGM in the pediatric population as compared to that in the adult population, or alternatively a clinical and/or technical justification for why pediatric data are not needed, must be provided and determined by FDA to be acceptable and appropriate.
(vii) Data must demonstrate that throughout the claimed sensor life, the device does not allow clinically significant gaps in sensor data availability that would prevent any digitally connected devices from achieving their intended use.
(2) Design verification and validation must include a detailed strategy to ensure secure and reliable means of iCGM data transmission to provide real-time glucose readings at clinically meaningful time intervals to devices intended to receive the iCGM glucose data.
(3) Design verification and validation must include adequate controls established during manufacturing and at product release to ensure the released product meets the performance specifications as defined in paragraphs (b)(1) and (b)(2) of this section.
(4) The device must demonstrate clinically acceptable performance in the presence of clinically relevant levels of potential interfering substances that are reasonably present in the intended use population, including but not limited to endogenous substances and metabolites, foods, dietary supplements, and medications.
(5) The device must include appropriate measures to ensure that disposable sensors cannot be used beyond its claimed sensor wear period.
(6) Design verification and validation must include results obtained through a usability study that demonstrates that the intended user can use the device safely and obtain the expected glucose measurement accuracy.
(7) The labeling required under § 809.10(b) of this chapter must include a separate description of the following sensor performance data observed in the clinical study performed in conformance with paragraph (b)(1) of this section for each intended use population, in addition to separate sensor performance data for each different iCGM insertion or use sites (
e.g., abdomen, arm, buttock):(i) A description of the accuracy in the following blood glucose concentration ranges: less than 54 mg/dL, 54 mg/dL to less than 70 mg/dL, 70 to 180 mg/dL, greater than 180 to 250 mg/dL, and greater than 250 mg/dL.
(ii) A description of the accuracy of positive and negative rate of change data.
(iii) A description of the frequency and duration of gaps in sensor data.
(iv) A description of the true, false, missed, and correct alert rates and a description of the available glucose concentration alert settings, if applicable.
(v) A description of the observed duration of iCGM life for the device.

Summary

0

EVALUATION OF AUTOMATIC CLASS III DESIGNATION FOR Dexcom G6 Continuous Glucose Monitoring System

DECISION SUMMARY

A. DEN Number:

DEN170088

B. Purpose for Submission:

De Novo request for evaluation of automatic class III designation for the Dexcom G6 Continuous Glucose Monitoring System

C. Measurand:

Glucose in Interstitial Fluid

D. Type of Test:

Quantitative, amperometric assay (Glucose Oxidase)

E. Applicant:

Dexcom, Inc.

F. Proprietary and Established Names:

G6 Continuous Glucose Monitoring System

G. Regulatory Information:

1. Regulation: 21 CFR 862.1355 2. Classification: Class II 3. Product code: OBJ 4. Panel: Chemistry (75)

H. Indications for Use:

1. Indications for Use:

The Dexcom G6 Continuous Glucose Monitoring System (Dexcom G6 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in

1

persons age 2 years and older.

The Dexcom G6 System is intended to replace fingerstick blood glucose testing for diabetes treatment decisions. Interpretation of the Dexcom G6 System results should be based on the glucose trends and several sequential readings over time. The Dexcom G6 System also aids in the detection of episodes of hyperglycemia and hypoglycemia, facilitating both acute and long-term therapy adjustments.

The Dexcom G6 System is also intended to autonomously communicate with digitally connected devices, including automated insulin dosing (AID) systems. The Dexcom G6 System can be used alone or in conjunction with these digitally connected medical devices for the purpose of managing diabetes.

1. Special conditions for use statement(s):
- This device is for prescription use only. ●
- . Remove the Dexcom G6 sensor, transmitter, and receiver before Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scan, or high-frequency electrical heat (diathermy) treatment. The magnetic fields and heat could damage the components of the Dexcom G6 System, which may cause it to display inaccurate blood glucose readings or may prevent alerts.
- . This device is not intended for pregnant women, people on dialysis, or critically ill patients.
- When wearing the device, ask for hand-wanding or full-body pat-down and visual inspection instead of going through the Advanced Imaging Technology (AIT) body scanner. Also avoid putting any part of the device through baggage x-ray machine.
- . The device should not be used to make diabetes treatment decisions when
  - o The user has not used the iCGM before or is unfamiliar with the Dexcom G6 System. (It may take days, weeks or months for a user to gain confidence in using the iCGM to make treatment decisions.)
  - The user's symptoms do not match the glucose values displayed by the o device.
  - The device does not show a glucose value or a trend arrow. O
  - During the first two hours of sensor warm-up period, the user should use a O blood glucose meter to make treatment decisions.
  - The user's glucose is rising or falling rapidly. o
- . Users should consult their healthcare practitioner and the user guide to understand how to make treatment decisions using this device.
- . The low and high glucose alerts should be set based on recommendations from a healthcare practitioner.
- Although standard dosing of acetaminophen (1000 mg per every 6 hours) does not appear to cause significant bias, higher supra-therapeutic levels of acetaminophen

2

have shown significant positive bias.

. The user should adhere to the calibration instructions and schedule for either the sensor code calibration or manual calibration options.
. Users should adhere to the instructions for sensor insertion site: Adult users should only use the abdomen and pediatric users should only use the buttock or abdomen. Sensor performance has not been evaluated in other insertion sites and may differ from expected iCGM performance.
Change your insertion site so it is at least 3 inches from the previous insertion site. Using the same site too often may cause irritation or scarring.
. Do not insert your sensor over irritated skin, tattoos, near waistband, bones, or scarring and near places that are easily bumped, pushed or laid on while sleeping.
Clean and dry your hands and the sensor insertion area before inserting the sensor to . avoid infection. Follow the cleaning instructions indicated in the user manual.
. If a sensor wire breaks or detaches from the sensor, it could remain under the user's skin. The user should contact their healthcare practitioner if this occurs.
. Do not use a damaged or cracked transmitter or receiver as this could cause injuries from electrical shocks and may impact the performance of the iCGM.
The transmitter is reusable. However, the transmitter should not be shared to avoid transmission of bloodborne illnesses and to ensure that the glucose readings, reports, alarms/alerts are correct.
. Components of the device are not compatible with previous generations of the device. Only use transmitters, receivers, and sensors from this system together.
The transmitter must remain within 20 feet of the receiver with no obstacles between them to ensure that the user will receive glucose values, important alerts and alarms.
. When using the smart device as a receiver, the user should follow the user manual instructions to ensure that all glucose values, important alarms and alerts can be seen and heard. Do not use headphones will using the smart device as a receiver. The app must always be running in the background of the smart device to ensure the user receives glucose values, alarms and alerts.
. Before updating the smart device hardware or operating system, verify the compatibility of the updated hardware/software with the device system.
Store your sensors only between 36° F and 86° F. Do not store sensors in the freezer. •
. Do not use sensors if they are expired or if sensor package is damaged.
. Do not submerge the receiver in water.
1. Special instrument requirements: Not applicable.

3

I. Device Description:

The Dexcom G6 System in an integrated continuous glucose monitoring system (iCGM) that provides continuous glucose readings which are updated every 5 minutes providing glucose levels, trends, and alerts. The System consists of three main components: a sensor, a Bluetooth Low Energy (BLE) transmitter and a BLE enabled display device (receiver and/or mobile application). The user can view glucose data on the receiver or on the G6 CGM App (i.e., a mobile medical application) running on a compatible mobile device, or on both simultaneously.

The system provides alerts and alarms which warn the user of low or impending low and high or impending high glucose levels. The user may determine their treatment based on the glucose values provided by the system.

G6 CGM SENSOR

The sensor component is a sterile device that consists of the sensor applicator, plastic base ("transmitter holder"), and sensor probe. The applicator is a single use, disposable unit that contains an introducer needle holding the sensor probe. The applicator deploys the needle and inserts the sensor under the skin. The needle is retracted back into the applicator after insertion. The sensor probe continuously measures glucose concentration in interstitial fluid and can be worn for up to 10 days.

The sensor may be worn in the abdomen for adults, and both the abdomen and buttock for children ages 2-17 years old. Sensor comes with a calibration code that the user enters into the system upon initializing a new sensor. Once the code is applied, the user does not need to calibrate the system throughout the entirety of the sensor lifetime, which is 10 days. However, the user has the option to manually calibrate the system using self-measurements from a blood glucose meter in addition to entering the calibration code. Alternatively, if the user chooses not to enter the calibration code, he or she must manually calibrate the sensor by entering two fingerstick blood glucose values during start up and every 24 hours thereafter.

G6 CGM TRANSMITTER

The G6 CGM Transmitter is a miniature radio transmitter that incorporates data processing functionality. The transmitter contains a Bluetooth radio transceiver for communication with a compatible display device (i.e., receiver and/or smart device). The transmitter attaches to the sensor and can be re-used for multiple sensing sessions up to three months.

G6 CGM RECEIVER

The G6 CGM Receiver is small hand-held device that wirelessly receives glucose information from the transmitter every five minutes and includes a touchscreen display. The

4

receiver displays the current glucose reading and glucose trends to the user. It alerts the user when glucose levels are outside of a target zone and when other important system conditions occur.

DEXCOM G6 System MOBILE APP

The G6 CGM App for iOS and G6 CGM App for Android provides an alternative display device to the receiver for users with a compatible, BLE-enabled smart device and behaves similarly to the receiver. The G6 CGM App is compatible with certain iOS, Android and Smart Device watches. A link to a list of compatible devices is included in the instructions for use.

The Dexcom G6 System is an interoperable connected device that can communicate glucose readings and other information wirelessly and securely to and from interoperable electronic interfaces; including compatible AID systems. The G6 CGM system is designed to communicate with interoperable devices in several ways, such as described below:

· Wireless communication from the transmitter directly to an interoperable device communicating through the same protocol.
· The app communicates to another app on a single mobile platform.
· The app communicates through the cloud to another software device.

J. Standard/Guidance Documents Referenced:

1. ISO 10993-1:2009/AC:2010; Biological evaluation of medical devices Part 1: Evaluation and testing within a risk management process
1. ISO 10993-3:2009: Biological Evaluation of Medical Devices Part 3: Tests For Genotoxicity, Carcinogenicity and Reproductive Toxicity
1. ISO 10993-5:2009; Biological Evaluation of Medical Devices Part 5: Tests for in vitro Cytotoxicity
1. ISO 10993-6:2016; Biological Evaluation of Medical Devices Part 6: Tests for Local Effects after Implantation
1. ISO 10993-10:2013; Biological evaluation of Medical Devices Part 10: Tests for Irritation and Skin Sensitization
1. ISO 10993-11; 2009; Biological Evaluation of Medical Devices Part 11: Test for Systemic Toxicity
1. ISO 11137-1:2006/A1:2013; Sterilization of Health Care Products-Radiation Part 1: Requirements for Development. Validation and Routine Control of a Sterilization Process for Medical Devices
1. ISO 11607-1:2014; Packaging for Terminally Sterilized Medical Devices Part 1: Requirements for Material. Sterile Barrier Systems, and Packaging Systems
1. ISO 11607-2:2006/A1:2014; Packaging for Terminally Sterilized Medical Devices Part 2: Validation Requirements for Forming, Sealing and Assembly Processes
1. ISO 11737-1:2006/AC:2009; Sterilization of Medical Devices Microbiological

5

Methods - Part 1: Determination of a Population of Microorganisms on Products

1. ISO 11737-2:2009; Sterilization of Medical Devices Microbiological Methods Part 2: Tests of Sterility Performed in the Definition, Validation and Maintenance of a Sterilization Process
1. ISO 23908:2013; Sharps Injury Protection. Requirements and Test Methods. Sharps Protection Features for Single-Use Hypodermic Needles, Introducers for Catheters and Needles Used for Blood Sampling
1. ISO 14971:2012; Medical Devices Application of Risk Management to Medical Devices
1. ISO 11137-3:2006; Sterilization of Health Care Products Radiation Part 3 Guidance on Dosimetric Aspects
1. ISO 7010:2012; Graphical Symbols Safety Colors and Safety Signs Registered Safety Signs
1. ISO 15223-1:2012; Medical Devices Symbols to be Used with Medical Device Labels, Labeling and Information to be Supplied - Part 1: General Requirements
1. ISO 15197:2013(E); In vitro diagnostic systems Requirements for blood glucose monitoring systems for self-testing in managing diabetes mellitus
1. ISO/TS 13004:2015; Sterilization of health care products Radiation Substantiation of selected sterilization dose: Method VDmax®
1. EN 62304:2006/AC:2008; Medical device software Software life cycle processes
1. EN 62304:2006/AC:2015; Medical device software Software life cycle processes
1. BS EN 62366:2015; Medical devices Application of usability engineering to medical devices
1. EN 60529:1991/A2:2013; Degrees of protection provided by enclosures (IP code)
1. BS EN 60529:1992 +A2:2013: Degrees of protection provided by enclosures (IP code)
1. EN 55011:2009 + A1:2010; Industrial, scientific and medical equipment. Radiofrequency disturbance characteristics. Limits and methods of measurement
1. EN 980:2008Symbols for use in the labelling of medical devices
1. EN 60601-1:2006/A1:2013; Medical electrical equipment Part 1: General requirements for basic safety and essential performance
1. EN 60601-1-2:2014; Medical electrical equipment Part 1-2: General requirements for basic safety and essential performance - Collateral standard: Electromagnetic compatibility - Requirements and tests
1. EN 55011:2016; Industrial, scientific and medical (ISM) equipment Radio Frequency disturbance characteristics - Limits and methods of measurement
1. EN 60601-1-6:2013; Medical Electrical Equipment Part 1-6: General Requirements for basic safety and essential performance - Collateral standard: Usability
1. IEC 60601-1-11:2015; Medical electrical equipment Part 1-11: General requirements

6

for basic safety and essential performance - Collateral standard: Requirements for medical electrical equipment and medical electrical systems used in home healthcare environment

1. ANSI/AAMI ES60601-1:2005/(R)2012 and A1:2012. C1:2009/(R)2012 and A2:2010/(R)2012; Medical electrical equipment - Part 1: General requirements for basic safety and essential performance
1. ASTM D4169-14; Standard practice for performance testing of shipping containers and systems
1. ASTM F2096-11; Standard test method for detecting gross leaks in packaging by internal pressurization
1. ASTM F88/F88M-15; Standard test method for seal strength of flexible barrier materials
1. ASTM F203-08; Standard practice for marking medical devices and other items for safety in the magnetic resonance environment
1. ANSI/AAMI/IEC 60601-1-8:2006 & A1:2012, IEC 60601-1:2006/A1:2013; MEDICAL ELECTRICAL EQUIPMENT – Part 1-8: General requirements for basic safety and essential performance - Collateral Standard: General requirements, tests and guidance for alarm systems in medical electrical equipment and medical electrical systems
1. IEC 60417-DB-12M:2002; Graphical symbols for use on equipment
1. IEC 60601-1-2:2014: Medical electrical equipment Part 1-2: General requirements for basic safety and essential performance - Collateral standard: Electromagnetic disturbances - Requirements and tests
1. IEC 61000-4-2:2008; Electromagnetic compatibility (EMC) Part 4-2: Testing and measurement techniques - Electrostatic discharge immunity test
1. IEC 61000-4-3:2010; Electromagnetic compatibility(EMC) Part 4-3: Testing and measurement techniques – Radiated, radio-frequency, electromagnetic field immunity test
1. IEC 61000-4-4:2012: Electromagnetic compatibility (EMC) Part 4-4: Testing and measurement techniques – Electrical fast transient/burst Immunity test
1. IEC 61000-4-5:2014; Electromagnetic compatibility(EMC) Part 4-5; Testing and measurement techniques - Surge immunity test
1. IEC 61000-4-6:2013; Electromagnetic compatibility(EMC) Part 4-6: Testing and measurement techniques - Immunity to conducted disturbances, induced by radiofrequency field
1. IEC 61000-4-8:2009; Electromagnetic compatibility(EMC) Part 4-8: Testing and measurement techniques - Power frequency magnetic field immunity test
1. IEC 60086-4:2014; Primary batteries Part 4: Safety of lithium batteries
1. IEC 61000-4-11:2004; Electromagnetic compatibility (EMC) Part 4-11: Testing and measurement techniques - Voltage dips, short interruptions and voltage variations immunitv tests

7

1. IEC 62133 Edition 2.0:2012; (Battery Cell) Secondary cells and batteries containing alkaline or other non-acid electrolytes - Safety requirements for portable sealed secondary cells, and for batteries made from them, for use in portable applications
1. IEC 60601-1-11:2015; Medical electrical equipment, Part 1-11: General requirements for basic safety and essential performance - Collateral standard: Requirements for medical electrical equipment and medical electrical systems used in the home healthcare environment
1. CISPR 11: 2015+AMD1:2016; Industrial, scientific and medical equipment Radiofrequency disturbance characteristics – Limits and methods of measurement
1. USP Chapter ; Pyrogen Test
1. USP Chapter ; Transfusion and infusion assemblies and similar medical devices -Bacterial Endotoxin and Pyrogen Tests
1. RTCA/DO-160G; Environmental Conditions and Test Procedures for Airborne Equipment, Section 20 Category T and Section 21 Category M
1. FCC: Part 15 (2016); Radio Frequency Devices, Conducted Limits, Section 15.207 and Section 15.247
1. FAA AC No. 91.21-1C; Use of Portable Electronic Devices Aboard Aircraft
1. UL 1642 Fifth Edition, Revision, March 15, 2012; Standard for Safety, Lithium Batteries
1. ANSI/HIBC 2.4 2013; Supplier Labeling Standard

K. Test Principle:

The Dexcom G6 System detects glucose levels from the fluid just beneath the skin (interstitial fluid). The sensor probe continuously measures glucose concentration in the interstitial fluid via an enzymatic electrochemical reaction using glucose oxidase. The enzyme, glucose oxidase, catalyzes the oxidation of glucose and produces hydrogen peroxide. The production of hydrogen peroxide generates an electrical current that is proportionate to the interstitial glucose concentration. The transmitter converts the signal using an algorithm to a glucose value read in mg/dL, which is then transmitted to the receiver for the user to see and use accordingly.

L. Performance Characteristics (if/when applicable):

1. Analytical performance:
- a. Reproducibility/Precision

iCGM performance was evaluated in clinical studies described in Section L(3) below. A subset of randomly-selected subjects (n=67) wore two devices concurrently (blinded and unblinded iCGM Systems) at the same sensor insertion site (abdomen or buttock) to evaluate the device precision. A table of the sensor and site distribution is provided below. A total of (b) (4) CGM-CGM matched pairs (match within the same

8

individual subject) contributed to the analysis. Mean absolute relative difference (between the 2 concurrently worn devices) was 9.6%; and mean coefficient of variation (CV) was 8.4%.

The following table shows that the agreement of readings from the two sensors for each insertion site. It should be noted that only the pediatric population may use both the abdomen and buttocks insertion sites. For adults (18+ years old) on abdomen, absolute relative difference (ARD) between the two Systems was 8.9% with CV of 7.9%. For pediatrics (2-5 years old) on upper buttocks, paired ARD was 5.2% with CV of 4.8%.

Another subset of randomly-selected (b) (4)	to evaluate agreement of	device measurements between different sensor insertion sites.
---------------------------------------------	--------------------------	---------------------------------------------------------------

| | Adults (18+
YO) -
Abdomen | Pediatrics (6-
17 YO) -
Abdomen | Pediatrics (6-
17 YO) -
Upper
Buttocks | Pediatrics (2-5
YO) - Upper
Buttocks | (b) (4) |
|-----------------------------------------------------|---------------------------------|---------------------------------------|-------------------------------------------------|--------------------------------------------|---------|
| CGM-CGM
Matched
Pairs (n) | 23,019 | 1,255 | 12,230 | 2,638 | |
| Number of
Subjects | 34 | 3 | 25 | 5 | |
| Paired
Absolute
Difference
(mg/dL) | 14.0 | 14.5 | 16.4 | 9.4 | |
| Paired
Absolute
Relative
Difference
(%) | 8.9 | 9.4 | 10.7 | 5.2 | |
| Coefficient of
Variation (%) | 7.9 | 7.6 | 8.5 | 4.8 | |

Precision by Insertion Site

b. Linearity/assay reportable range:

The reportable range for the G6 CGM is 40 to 400 mg/dL. Data supporting this claimed measurement range was generated in the clinical study described in Section

9

L(3) below.

c. Traceability, Stability, Expected values (controls, calibrators, or methods):
The G6 CGM sensor has a storage shelf-life of (b) (4) and testing is on-going. Shelf life was evaluated at 32°-86° F and 10-90% relative humidity.

The G6 CGM Transmitter has sufficient battery life to function for 3 months as intended following its maximum storage time of(b) (4) Shelf life was evaluated at 32°-113° F and 10-95% relative humidity.

d. Detection limit
If a glucose measurement is less than 40 mg/dL, the result is displayed by the system as 'Lo'. If a glucose measurement exceeds 400 mg/dL, result is displayed as 'Hi'. Data supporting this claimed measurement range was generated in the clinical study described in Section L(3) below.
e. Analytical specificity:
Certain endogenous and exogenous substances in the interstitial fluid may interfere with iCGM measurements. The types of potential interference and the extent of bias are dependent on the test principle of the particular iCGM technology. For this technology, acetaminophen has previously been shown to present significant interference in earlier generations of similar Dexcom Systems approved under the product code MDS (e.g., Dexcom G4 (P120005) and G5 (P120005/S033) Systems) and has been contraindicated in those types of CGM systems.

acetaminophen Formal testing was conducted with both acetaminophen dose response bench testing and clinical validation. During clinical testing, all medications for which the subject was using or had used over the course of the study along with frequency of use were recorded. Both studies did not include exclusion criteria based on medications or vitamin use.

The G6 CGM sensor was designed to reduce interference from acetaminophen. A clinical study was performed to evaluate acetaminophen interference for the G6 CGM System. It is a prospective, multi-center, single-arm study that enrolled 70 subjects at 4 sites. The study was designed to evaluate the effectiveness of the G6 CGM sensor in blocking the interference of acetaminophen on iCGM readings in adult subjects (18 or older) with diabetes mellitus.

The clinical study included a single session to evaluate the G6 CGM System in blocking the interference of acetaminophen as measured by iCGM performance. Subjects wore two iCGM systems, the G6 system and the G4 CGM (P120005), on the abdomen for approximately 5 days. Subjects participated in one clinic session on day 4 or 5 after sensor insertion. A single 1.000 mg dose of acetaminophen was orally

10

administered to the subject during the clinic session. Both a laboratory-based blood glucose measurement method (Yellow Springs Instrument 2300 STAT plus Glucose analyzer) and fingerstick blood glucose testing using a blood glucose meter were performed at regular intervals before and after acetaminophen ingestion.

The interference effect on the iCGM system was evaluated by comparing the bias in the glucose values from the iCGM systems after administration of 1000 mg of acetaminophen to glucose values prior to acetaminophen dosing. Bias was calculated by taking the difference in glucose measurements between iCGM and laboratory blood glucose values. A G4 CGM sensor was used as a comparator for establishing the time from acetaminophen dose to a maximum bias and the duration of bias in the interstitial fluid.

Study data indicates that a single dose of 1000 mg does not introduce significant interference to the device. The accuracy and percentage agreement of the Dexcom G6 System Sensor and the laboratory comparator method are described in the tables below. The mean absolute relative difference (MARD) increased 1% (7% pre-dose vs. 8%

post-dose). The sensor values within %15/15mg/dL of laboratory comparator method values decreased by 3%, and the sensor values within %20/20 mg/dL to %40/40 mg/dL within laboratory comparator method values did not change.

| 60-
minute
Window | # of Pairs | Mean
Bias | Mean
Absolute
Difference | Mean
Relative
Difference | Mean
Absolute
Relative
Difference |
|-------------------------|------------|--------------|--------------------------------|--------------------------------|--------------------------------------------|
| Pre-dose | 446 | +6 | 10 | +4% | 7% |
| Post-dose | 389 | +9 | 11 | +7% | 8% |

Accuracy of the sensor 60 minutes before and after acetaminophen intake compared to laboratory comparator method

Percentage agreement of the sensor and laboratory comparator method 60 minutes before and after acetaminophen intake

| 60-minute
Window | # of Pairs | %15/15
mg/L
within
comparator
method
values | %20/20
mg/dL
within
comparator
method | %30/30
mg/dL
within
comparator
method | %40/40
mg/dL
within
comparator
method |
|---------------------|------------|------------------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|
| Pre-dose | 446 | 91% | 96% | 100% | 100% |
| Post-dose | 389 | 87% | 96% | 100% | 100% |

In addition, an outlier analysis was conducted to determine whether there was any observational relationship that existed between medication or vitamin use and G6 sensor performance. An outlier condition of percent of values within %20/20 mg/dL of laboratory comparator method value accuracy rate of ≤35% was selected to

11

evaluate the relationship between concomitant medications and low sensor accuracy. This acceptance criteria was based on the distribution of the %20/20 mg/dL accuracy rate across all subject participants within the clinical accuracy studies (n=324).

Based on the results of the clinical evaluation, the following statements have been placed in the device labeling:

. "With the Dexcom G6 System, you can take a standard acetaminophen dose and still use the Dexcom G6 System readings. Taking higher than recommended doses of acetaminophen (e.g. > 1 gram every 6 hours in adults) may affect the Dexcom G6 System reading and make them look higher than they really are."
"A clinical study including 65 adults was performed to demonstrate acetaminophen does not significantly interfere with iCGM readings. The difference in biases of the Dexcom G6 System was measured inreference to the laboratory comparator before and after 1 gram acetaminophen intake. This difference was defined as the maximum interference effect (MIE) defined as the maximum bias post-dose subtracted by the mean baseline bias. The mean MIE of the C6 sensor was 5.2 mg/dL (max bias post dose - max bias pre-dose using laboratory comparator reference) and was statistically significantly lower than the performance goal of 10 mg/dL (one-sided upper 95% CI of 6.4 mg/dL, p ~2-3 times therapeutic levels) levels of acetaminophen has shown significant bias."

2. Comparison studies:

a. Method comparison with predicate device:
Not applicable.
b. Matrix comparison:

12

Not applicable. Interstitial fluid is the only indicated matrix.

3. Clinical studies:

Two clinical studies were conducted to support the accuracy performance of the device:

| Study Name | Patient
Population | Study Objective |
|---------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Effectiveness and Safety
of the Dexcom™ G6
Continuous Glucose
Monitoring System
(Study 1) | 2 years and
older
Type 1 or
Type 2
Diabetes

Enrolled:
n=304

Completed:
n=262 | Pivotal study to evaluate effectiveness and
safety of the G6 Continuous Glucose
Monitoring System compared to a
laboratory blood glucose measurement
method in Type 1 and Type 2 diabetic
subjects aged 2 years and older. |
| Effectiveness and Safety
of the Dexcom™ G6
Continuous Glucose
Monitoring System with
an Automated Applicator
(Study 2) | 6 years and
older
Type 1 or
Type 2
Diabetes

Enrolled:
n=76

Completed:
n=62 | Sub-Study to demonstrate comparability
of the performance of the Dexcom G6
System with Automated Sensor
Applicator (auto-applicator) to the
performance of the Dexcom G6 System
observed in the pivotal study referenced
above which used a manual applicator. |

Study 1 and Study 2 have different sensor applicator mechanisms and the applicator configuration in Study 2 will be the marketed version of the device. Dexcom conducted Study 2 to demonstrate comparable performance of the two device configurations. Results of these two studies are presented below together.

To demonstrate the accuracy performance of the Dexcom G6 System, two prospective clinical studies were conducted at 11 centers across the United States. The studies included both adult (18 years and older) and pediatric (2 to 17 years) participants. The studies enrolled a total of 380 adult (18 years and older) and pediatric (2 to 17 years) participants with 99% having Type 1 diabetes mellitus and 1% having insulin-using Type 2 diabetes mellitus. A total of 324 subjects completed the studies.

Participants wore either one or two sensors for up to 10 days. A subset of participants

13

wore two sensors for the precision study to compare variability of readings between sensors (see Section L(1)(a) above). Adult participants wore their Dexcom G6 System (s) in the abdomen only; pediatric subjects had the choice of either abdomen or upper buttocks. Clinic session(s) took place on Day 1, Day 4-5, Day 7, and/or Day 10. Depending on the participant's age, they participated in either 1, 2 or 3 clinic sessions of varying duration.

In Study 1, under close observation by the study investigator staff, the glucose levels of study participants 13 years and older were deliberately manipulated per a protocol to raise or lower blood glucose levels to assess performance over the range that iCGM measures glucose (40-400 mg/dl). In Study 2, participants managed their glucose as they normally do: glucose was not deliberately manipulated.

. Adult subjects: Two or three 12-hour clinic sessions compared to laboratory blood glucose comparator method.
. Pediatrics 13-17 years: One 12 hour clinic session compared to laboratory blood glucose comparator method with glucose manipulation.
. Pediatrics 6-12 years: One 6 hour clinic session compared to laboratory blood glucose comparator method but no glucose manipulation.
. Pediatrics 2-5 years: One 4 hour clinic session compared to blood glucose meter comparator method.

Accuracy of the Dexcom G6 System was evaluated by comparing iCGM values obtained at the same or similar time points to the comparator methods. In the studies below, the absolute differences in ms/dL of values compared to the of the comparator method were calculated for all values below 70 mg/dL. For all values 70 mg/dL and above, percentage differences compared to the comparator method were calculated.

The following tables present the data from the clinical studies:

| iCGM
Glucose
Range | Matched
Pairs (N) | Percent
Within
15
mg/dL
(95%
LB) | Percent
Within
40
mg/dL
(95%
LB) | Percent
Within
15%
(95%
LB) | Percent
Within
40%
(95%
LB) | Mean
Bias
(mg/dL)
(95%
UB) |
|--------------------------|----------------------|-------------------------------------------------|-------------------------------------------------|-----------------------------------------|-----------------------------------------|----------------------------------------|
| 180
mg/dL | 7,956 | --- | --- | 85.5
(82.8) | 99.9
(99.9) | -7.0 (-
3.9) |

Percent and Point Accuracy by iCGM Glucose Range: Adults (N=159)

*95% LB is the lower bound of the confidence interval and 95% UB is the upper bound of the confidence interval

14

| iCGM
Glucose
Range | Matched
Pairs
(N) | Percent
Within
15
mg/dL
(95%
LB) | Percent
Within
40
mg/dL
(95%
LB) | Percent
Within
15%
(95%
LB) | Percent
Within
40%
(95%
LB) | Mean Bias
(mg/dL)
(95% UB) |
|--------------------------|-------------------------|-------------------------------------------------|-------------------------------------------------|-----------------------------------------|-----------------------------------------|----------------------------------|
| 180
mg/dL | 2,276 | ---- | ---- | 85.8
(81.7) | 99.9
(99.8) | 2.9 (6.5) |

Percent and Point Accuracy by iCGM Glucose Range: Pediatrics (N=165)

*95% LB is the lower bound of the confidence interval and 95% UB is the upper bound of the confidence interval

Percent and Point Accuracy by Comparator Glucose Range: Adults (N=159)

| Comparator
Glucose
Range | Matched
Pairs (N) | Percent
Within
15
mg/dL
(95%
LB) | Percent
Within
40
mg/dL
(95%
LB) | Percent
Within
15%
(95%
LB) | Percent
Within
40%
(95%
LB) | Mean
Bias
(mg/dL)
(95%
UB) |
|--------------------------------|----------------------|-------------------------------------------------|-------------------------------------------------|-----------------------------------------|-----------------------------------------|----------------------------------------|
| 180 mg/dL | 8,350 | | | 83.2
(80.1) | 99.8
(99.7) | -10.5 (-
7.5) |

*95% LB is the lower bound of the confidence interval and 95% UB is the upper bound of the confidence interval

Percent and Point Accuracy by Comparator Glucose Range: Pediatrics (N=165)

| Comparator
Glucose
Range | Matched
Pairs
(N) | Percent
Within
15
mg/dL
(95%
LB) | Percent
Within
40
mg/dL
(95%
LB) | Percent
Within
15%
(95%
LB) | Percent
Within
40%
(95%
LB) | Mean
Bias
(mg/dL)
(95% UB) |
|--------------------------------|-------------------------|-------------------------------------------------|-------------------------------------------------|-----------------------------------------|-----------------------------------------|-------------------------------------|
| 180 mg/dL | 2,317 | | | 85.0
(80.2) | 99.9
(99.7) | -1.8 (2.1) |

*95% LB is the lower bound of the confidence interval and 95% UB is the upper bound of the confidence interval

15

Percent of values within 20% of comparator method were calculated across the measuring range overall, and for pediatric and adult populations.

| iCGM Glucose Range | Matched Pairs (N) | Percent within 20%
(95% LB) |
|--------------------------------|-------------------|--------------------------------|
| Overall (40-400 mg/dL) | 25,101 | 89.9 (88.7) |
| Adults (18 years and up) | 19,329 | 89.5 (88.2) |
| Pediatrics (6-17 years
old) | 5,772 | 91.0 (88.7) |
| Pediatrics (2-5 years
old)* | 82 | 92.7 (86.6) |

Percent of iCGM values within 20% of reference blood glucose

Subjects 2-6 years old were compared to an SMBG reference

*95% LB is the lower bound of the confidence interval

Percent of values within 15%/15 mg/dL, 20%/20 mg/dL, and 40%/40 mg/dL stratified by glucose ranges of 250 mg/dL for iCGM and laboratory comparator were also provided for abdominal insertion site in adult subjects, and both buttock and abdominal insertion site in pediatric populations. For pediatric subjects ages 6 and under, values were compared to SMBG.

Dexcom G6 System Accuracy to Comparator (comp) within iCGM Glucose Ranges (Adults: n=159)

| iCGM
Glucose
Range1
(mg/dL) | Number
of paired
iCGM-
comp | Percent
within
15
mg/dL | Percent
within
20
mg/dL | Percent
within
40
mg/dL | Percent
within
15% | Percent
within
20% | Percent
within
40% | Mean
bias
(mg/dL) | MARD
(%) |
|--------------------------------------|--------------------------------------|----------------------------------|----------------------------------|----------------------------------|--------------------------|--------------------------|--------------------------|-------------------------|-------------|
| 250 | 3,863 | --- | --- | --- | 91.1 | 97.7 | 100.0 | -3.8 | 7.1 |

16

| iCGM
Glucose
Range1
(mg/dL) | Number
of paired
iCGM-
comp | Percent
within
15
mg/dL | Percent
within
20
mg/dL | Percent
within
40
mg/dL | Percent
within
15% | Percent
within
20% | Percent
within
40% | Mean
bias
(mg/dL) | MARD
(%) |
|--------------------------------------|--------------------------------------|----------------------------------|----------------------------------|----------------------------------|--------------------------|--------------------------|--------------------------|-------------------------|-------------|
| 250 | 916 | | | | 89.3 | 95.9 | 99.9 | 9.2 | 7.4 |

Dexcom G6 System Accuracy to Comparator (comp) within iCGM Glucose Ranges (Pediatrics; n=165)

1CGM readings are within 40-400 mg/dL, inclusive.

Dexcom G6 System Accuracy to Comparator (comp) within iCGM Glucose Ranges (Pediatrics, Abdomen; n=99)

| iCGM
Glucose
Range1
(mg/dL) | Number
of paired
iCGM-
comp | Percent
within
15
mg/dL | Percent
within
20
mg/dL | Percent
within
40
mg/dL | Percent
within
15% | Percent
within
20% | Percent
within
40% | Mean
bias
(mg/dL) | MARD
(%) |
|--------------------------------------|--------------------------------------|----------------------------------|----------------------------------|----------------------------------|--------------------------|--------------------------|--------------------------|-------------------------|-------------|
| 250 | 574 | | | | 89.2 | 96.5 | 99.8 | 8.0 | 7.5 |

17

| iCGM
Glucose
Range1
(mg/dL) | Number
of paired
iCGM-
comp | Percent
within
15
mg/dL | Percent
within
20
mg/dL | Percent
within
40
mg/dL | Percent
within
15% | Percent
within
20% | Percent
within
40% | Mean
bias
(mg/dL) | MARD
(%) |
|--------------------------------------|--------------------------------------|----------------------------------|----------------------------------|----------------------------------|--------------------------|--------------------------|--------------------------|-------------------------|-------------|
| 250 | 342 | | | | 89.5 | 94.7 | 100.0 | 11.1 | 7.3 |

Dexcom G6 System Accuracy to Comparator (comp) within iCGM Glucose Ranges (Pediatrics, Buttocks; n=66)

1CGM readings are within 40-400 mg/dL, inclusive.

Dexcom G6 System Accuracy to Comparator (comp) within Comparator Glucose Ranges (Adults; n=159)

| Glucose
Range
(mg/dL) | Number
of paired
iCGM-
comp | Percent
within
15
mg/dL | Percent
within
20
mg/dL | Percent
within
40
mg/dL | Percent
within
15% | Percent
within
20% | Percent
within
40% | Mean
bias
(mg/dL) | MARD
(%) |
|-----------------------------|--------------------------------------|----------------------------------|----------------------------------|----------------------------------|--------------------------|--------------------------|--------------------------|-------------------------|-------------|
| 250 | 4,410 | | | | 83.4 | 93.3 | 99.8 | -13.5 | 8.6 |

18

| Glucose
Range
(mg/dL) | Number
of paired
iCGM-
comp | Percent
within
15
mg/dL | Percent
within
20
mg/dL | Percent
within
40
mg/dL | Percent
within
15% | Percent
within
20% | Percent
within
40% | Mean
bias
(mg/dL) | MARD
(%) |
|-----------------------------|--------------------------------------|----------------------------------|----------------------------------|----------------------------------|--------------------------|--------------------------|--------------------------|-------------------------|-------------|
| 250 | 916 | | | | 85.2 | 94.0 | 100.0 | -3.3 | 8.0 |

Dexcom G6 System Accuracy to Comparator (comp) within Comparator Glucose Ranges (Pediatrics; n=165)

1CGM readings are within 40-400 mg/dL, inclusive.

Dexcom G6 System Accuracy to Comparator (comp) within Comparator Glucose Ranges (Pediatrics, Abdomen; n=99)

| Glucose
Range
(mg/dL) | Number
of paired
iCGM-
comp | Percent
within
15
mg/dL | Percent
within
20
mg/dL | Percent
within
40
mg/dL | Percent
within
15% | Percent
within
20% | Percent
within
40% | Mean
bias
(mg/dL) | MARD
(%) |
|-----------------------------|--------------------------------------|----------------------------------|----------------------------------|----------------------------------|--------------------------|--------------------------|--------------------------|-------------------------|-------------|
| 250 | 602 | | | | 85.4 | 95.8 | 100.0 | -3.9 | 8.1 |

19

| Glucose
Range
(mg/dL) | Number
of paired
iCGM-
comp | Percent
within
15 mg/dL | Percent
within
20 mg/dL | Percent
within
40 mg/dL | Percent
within
15% | Percent
within
20% | Percent
within
40% | Mean
bias
(mg/dL) | MARD
(%) |
|-----------------------------|--------------------------------------|-------------------------------|-------------------------------|-------------------------------|--------------------------|--------------------------|--------------------------|-------------------------|-------------|
| 250 | 314 | | | | 84.7 | 90.4 | 100.0 | -2.1 | 7.8 |

Dexcom G6 System Accuracy to Comparator (comp) within Comparator Glucose Ranges (Pediatrics, Buttocks; n=66)

20

Concurrence of iCGM values compared to the comparator method across the entire measuring range was also evaluated. iCGM glucose ranges of 400 mg/dL were evaluated against comparator glucose ranges and percent of iCGM values within those ranges were reported.

| iCGM
Glucose
Range1

(mg/dL)	Comparator Glucose Values (mg/dL, n=159)											Total
	400
400	.	.	.	.	.	.	.	.	5.9%	76.5%	17.6%	34

Concurrence of Dexcom G6 System Readings and Comparator Values by iCGM Glucose Range (Adults; n=159)

21

| iCGM
Glucose
Range1
(mg/dL) | 400 | Total |
|--------------------------------------|------|-------|-------|--------|-------------|-------------|-------------|-------------|-------------|-------------|-------|-------|
| 400 | . | . | . | . | . | . | . | . | 5.0% | 55.0% | 40.0% | 20 |

Concurrence of Dexcom G6 System Readings and Comparator Values by iCGM Glucose Range (Pediatrics; n=165)

22

| iCGM
glucose
range1

(mg/dL)	Comparator Glucose Range (mg/dL)
	400
400	.	.	.	.	.	.	.	.	0.1%	5.9%	26.1%
Total	27	1,180	2,191	3,503	2,910	2,457	2,755	2,383	1,601	437	23

Concurrence of Dexcom G6 System Readings and Comparator Values by Comparator Glucose Range (Adults, n=159)

23

| iCGM
glucose
range
(mg/dL) | 400 |
|-------------------------------------|-------|-------|-------|--------|-------------|-------------|-------------|-------------|-------------|-------------|-------|
| Comparator Glucose Range (mg/dL) | | | | | | | | | | | |
| 400 | . | . | . | . | . | . | . | . | 0.4% | 14.9% | 80.0% |
| Total | 2 | 127 | 559 | 1,254 | 1,081 | 955 | 913 | 570 | 282 | 74 | 10 |

Concurrence of Dexcom G6 System Readings and Comparator Values by Comparator Glucose Range (Pediatrics; n=165)

24

Trend Accuracy

Trend accuracy describes the accuracy of the sensor during times of rapidly changing glucose and are characterized by slopes, such as from >2 mg/dL to 2 | |
| 2 | 0.1% | 0.1% | 0.8% | 5.6% | 22.1% | 71.3% | 1,367 |

Trend Accuracy (Adults; n=159)

Trend Accuracy (Pediatrics; n=165)

| iCGM
Rate Range
(mg/dL/min) | Comparator Rate Range (mg/dL/min) | | | | | | iCGM-comparator Pairs
(n) |
|-----------------------------------|-----------------------------------|---------|---------|-------|-------|-------|------------------------------|
| | 2 | |
| 2 | 0.0% | 0.5% | 1.7% | 7.1% | 23.6% | 67.1% | 423 |

Agreement When iCGM Reads "LOW" or "HIGH"

The Dexcom G6 System reports glucose readings between 40 and 400 mg/dL. When the system determines the glucose reading is below 40 mg/dL, it displays "LOW" in the Receiver or Mobile Application Status Box. When the system determines that the glucose level is above 400 mg/dL, it displays "HIGH" in the Receiver or Mobile Application Status Box. Because the System does not display glucose values below

25

40 mg/dL or above 400 mg/dL, the comparisons to the actual blood glucose levels (as determined by the laboratory comparator analyzer) when the iCGM value is classified as "LOW" or "HIGH" is evaluated separately, and the cumulative percentages when laboratory comparator values were less than certain glucose levels (for "LOW"), and when laboratory comparator values were greater than certain glucose levels (for "HIGH") are presented in the table below.

| iCGM
Readings | iCGM-
comparator
Pairs | 340 | > 320 | > 280 | > 250 | ≤ 250 | Total |
| | n | 53 | 53 | 54 | 54 | 0 | 54 |

Distribution of Reference Values when CGM Readings are 'Low' or 'High'

Alert performance:

The Hypoglycemic Alert Rate shows how often the alert is right or wrong. The True Notification Rate is the % of time the device alarmed when the blood glucose level was at or below the alert setting within 15 minutes before or after the device alarmed (as confirmed by the comparator method). The False Notification Rate is the % of time the device alarmed when the blood glucose level was above the alert setting within 15 minutes before or after the device alarmed. The Correct Detection Rate is the % of time the device alarmed when the blood glucose level was at or below the alert setting within 15 minutes before or after the hypoglycemic event. The Missed Detection Rate is the % of time the device did not alarm when the blood glucose level was at or below the alert setting within 15 minutes before and after the hypoglycemic event.

26

| Alert
Setting | Hypo
Events
(n) | Correct
Detection
Rate (%) | Missed
Detection
Rate (%) | Hypo
Alerts
(n) | True
Notification
Rate (%) | False
Notification
Rate (%) |
|------------------|-----------------------|----------------------------------|---------------------------------|-----------------------|----------------------------------|-----------------------------------|
| 55
mg/dL | 642 | 63.9% | 36.1% | 1,408 | 66.6% | 33.4% |
| 60
mg/dL | 1,158 | 74.1% | 25.9% | 2,370 | 74.6% | 25.4% |
| 70
mg/dL | 2,365 | 86.0% | 14.0% | 5,079 | 85.5% | 14.5% |
| 80
mg/dL | 3,372 | 92.7% | 7.3% | 8,187 | 89.1% | 10.9% |
| 90
mg/dL | 4,287 | 94.6% | 5.4% | 11,147 | 9.4% | 10.6% |

Hypoglycemic Alert and Detection Rate Evaluations (Adults, n=1591)

All subjects were considered in the analysis; however, not all subjects experienced hypo event

| Alert
Setting | Hypo
Events
(n) | Correct
Detection
Rate (%) | Missed
Detection
Rate (%) | Hypo
Alerts
(n) | True
Notification
Rate (%) | False
Notification
Rate (%) |
|------------------|-----------------------|----------------------------------|---------------------------------|-----------------------|----------------------------------|-----------------------------------|
| 55 mg/dL | 66 | 68.2 | 31.8 | 358 | 31.6% | 68.4 |
| 60 mg/dL | 119 | 73.1 | 26.9 | 521 | 44.1% | 55.9 |
| 70 mg/dL | 369 | 81.6 | 18.4 | 1,054 | 68.0% | 32.0 |
| 80 mg/dL | 671 | 88.1 | 11.9 | 1,794 | 80.5% | 19.5 |
| 90 mg/dL | 1,030 | 92.8 | 7.2 | 2,746 | 86.3% | 13.7 |

Hypoglycemic Alert and Detection Rate Evaluations (Pediatrics, n=165)

All subjects were considered in the analysis; however, not all subjects experienced hypo event

The Hyperglycemic Alert Rate shows how often the alert is right or wrong. The True Notification Rate is the % of time the device alarmed when the blood glucose level was at or above the alert setting within 15 minutes before or after the device alarmed. The False Notification Rate is the % of time the device alarmed when the blood glucose level was below the alert setting within 15 minutes before or after the device alarmed. The Correct Detection Rate is the % of time the device alarmed when the blood glucose level was at

27

or above the alert setting within 15 minutes before or after the hyperglycemic event. The Missed Detection Rate is the % of time the device did not alarm when the blood glucose level was at or above the alert setting within 15 minutes before and after the hyperglycemic event.

| Alert
Setting | Hyper
Events
(n) | Correct
Detection
Rate (%) | Missed
Detection
Rate (%) | Hyper
Alerts
(n) | True
Notification
Rate
(%)97.5% | False
Notification
Rate (%) |
|------------------|------------------------|----------------------------------|---------------------------------|------------------------|------------------------------------------|-----------------------------------|
| 120
mg/dL | 12,664 | 97.6 | 2.4 | 37,061 | 97.5% | 2.5 |
| 140
mg/dL | 11,175 | 96.8 | 3.2 | 32,148 | 97.2% | 2.8 |
| 180
mg/dL | 8,455 | 95.2 | 4.8 | 23,424 | 96.6% | 3.4 |
| 200
mg/dL | 7,265 | 93.6 | 6.4 | 19,586 | 96.0% | 4.0 |
| 220
mg/dL | 6,143 | 91.2 | 8.8 | 15,689 | 95.6% | 4.4 |
| 240
mg/dL | 5,007 | 88.7 | 11.3 | 12,279 | 94.6% | 5.4 |
| 300
mg/dL | 2,095 | 74.8 | 25.2 | 4,211 | 85.9% | 14.1 |

Hyperglycemic Alert and Detection Rate Evaluations (Adults; n=157)

28

| Alert
Setting | Hyper
Events
(n) | Correct
Detection
Rate (%) | Missed
Detection
Rate (%) | Hyper
Alerts
(n) | True
Notification
Rate (%) | False
Notification
Rate (%) |
|------------------|------------------------|----------------------------------|---------------------------------|------------------------|----------------------------------|-----------------------------------|
| 120
mg/dL | 3,930 | 97.8 | 2.2 | 11,683 | 97.3% | 2.7 |
| 140
mg/dL | 3,388 | 97.7 | 2.3 | 10,113 | 96.2% | 3.8 |
| 180
mg/dL | 2,366 | 94.7 | 5.3 | 6,821 | 93.4% | 6.6 |
| 200
mg/dL | 1,874 | 91.2 | 8.8 | 5,190 | 93.3% | 6.7 |
| 220
mg/dL | 1,453 | 91.7 | 8.3 | 4,096 | 90.4% | 9.6 |
| 240
mg/dL | 1,093 | 90.2 | 9.8 | 3.068 | 86.9% | 13.1 |
| 300
mg/dL | 374 | 84.8 | 15.2 | 1,010 | 77.2% | 22.8 |

Hyperglycemic Alert and Detection Rate Evaluations (Pediatric; n=165)

Sensor Stability:

Sensor stability describes the performance over the sensor lifetime. Sensors can be worn for up to 10 days. Performance was estimated by calculating the percentage of Dexcom G6 System readings within 15 mg/dL or 15% (15/15%), 20 mg/dL or 20% (20/20%), and 40 mg/dL or 40% (40/40%) of the laboratory comparator values at the beginning (Day 1, 2), middle (Day 4, 5), and end (Day 7, 10) of the Dexcom G6 System lifecycle. The mean of the absolute relative differences were evaluated over the 10-day life of the sensor within the measuring range.

29

| Wear Period | Number of
paired iCGM-
comparator | MARD
(%) | Percent
within
15/15%
(%) | Percent
within
20/20%
(%) | Percent
within
40/40%
(%) |
|-------------|-----------------------------------------|-------------|------------------------------------|------------------------------------|------------------------------------|
| Beginning | 8,863 | 10.7 | 77.6 | 89.0 | 99.6 |
| Middle | 7,732 | 9.2 | 84.1 | 94.4 | 99.8 |
| End | 8,506 | 9.6 | 82.6 | 92.0 | 99.5 |

Sensor Stability Relative to Comparator (Accuracy Over Time)

Sensor Life:

A total of 374 sensors were evaluated to determine the percentage of sensors that lasted through the 10 day sensor life. Eighty-four percent (84%) of the sensors lasted through the end of the entire wear period (e.g., Day 10) (see Figure 1). Among the 374 sensors evaluated, 36 sensors (9.6%) had "early sensor shut-off" where the sensor algorithm would have detected sensors that did not function as intended and shut them off.

Sensor Survival Rate by Wear Day (Adults, n=164)

Wear Day	Number of Sensors	Survival Rate (%)
1	162	99.4%
2	160	98.8%
3	158	98.8%
4	155	98.8%
5	154	98.1%
6	154	98.1%
7	150	96.8%
8	146	96.2%
9	144	94.9%
10	139	93.5%

30

Wear Day	Number of Sensors	Survival Rate (%)
1	206	99.0%
2	204	99.0%
3	196	97.1%
4	193	95.6%
5	184	91.1%
6	175	88.6%
7	164	85.5%
8	157	83.4%
9	146	79.2%
10	142	76.8%

Sensor Survival Rate by; Wear Day (Pediatrics, n=210)

The capture rate characterizes the reliability of the communication between components of the system. The Dexcom G6 System provides a sensor glucose reading every 5 minutes, or up to 288 readings per day. The percentage of readings expected to be received from the system over the sensor life was evaluated from 374 sensors and is 98.6%. More than 97% of the sensors captured readings at least 90% of the time. The table below describes the percent of readings received throughout the life span of the sensor (capture rate).

Wear Day	Number of Sensors	Capture Rate (%)
1	374	97.6
2	368	98.6
3	364	98.7
4	354	98.6
5	348	98.5
6	338	98.5
7	329	98.2
8	314	97.8
9	303	97.0
10	290	96.4

Reading Capture Rate by Wear Day

31

Human Factors:

Human factors and usability of the device were evaluated to determine whether the user interface design and labeling would impact the performance of the device. Specific use scenarios and tasks the user would have to carry out correctly in order to use the device safely were identified. All critical tasks for which a use error could lead to high severity harm and the subject device user interface was evaluated. The compiled data provided assessment that use-related risks have been addressed and that further risk reduction is not necessary. Representative use for all critical tasks in the Dexcom G6 System which included but was not limited to interactions around calibration, detection of sensor placement, alerts, training, and labeling were evaluated. An analysis of hazards and risks was conducted on the Dexcom G6 System to determine safety risks associated with use of the system. The testing was carried out according to the FDA Guidance titled Applying Human Factors and Usability Engineering to Medical Devices, dated February 3, 2016, and IEC 60601-1-11:2015 titled Medical Electrical Equipment- General requirements for basic safety and essential performance.

4. Expected Values

Not applicable.

M. Instrument Name:

Dexcom G6 Continuous Glucose Monitoring System

N. System Description:

1. Modes of Operation:
  Does the applicant's device contain the ability to transmit data to a computer, webserver, or mobile device? Yes X or No

Does the applicant's device transmit data to a computer, webserver, or mobile device using wireless transmission: Yes X or No ------------------------------------------------------------------------------------------------------------------------------

1. Software:
  FDA has reviewed applicant's Hazard Analysis and software development processes for this line of product types:

Yes

1. Specimen Identification:
  Not Applicable
1. Specimen Sampling and Handling:

32

Not Applicable

4. Calibration:

Though the Dexcom G6 System does not require user calibration, users of the Dexcom G6 System have the option to calibrate the device manually (e.g., in situations where users do not have to use the calibration code). Therefore, a calibration stability evaluation was completed to demonstrate that the system could be calibrated manually without impact to system performance. Subjects were instructed to calibrate their CGM devices according to the explicit system requirements. Beginning two hours after sensor insertion, calibration prompts were provided on the receiver twice the first day and every 24 hours for the remainder of the study. To demonstrate the performance of the System over a calibration cycle, the CGM-laboratory comparator percentage agreement was evaluated in 4-hour increments after calibration. Results were similar to the results obtained using the factory calibration codes.

1. Quality Control:
  Not Applicable

O. Other Supportive Instrument Performance Characteristics Data Not Covered In the "Performance Characteristics" Section above:

Biocompatibility:

Biocompatibility testing was performed on the sterile components of the Dexcom G6 System (sensor, transmitter, and applicator system) using the guidelines described in ISO 10993-1 Biological Evaluation of Medical Devices – Part 1: Evaluation and Testing.

The sensor was tested as an implant device that is tissue/bone contacting for permanent contact whose multiple use or contact exceeds 30 days. The following tests were conducted:

. Cytotoxicity
Sensitization
Irritation or intracutaneous reactivity ●
Systemic toxicity ●
Subacute/Subchronic toxicity ●
Genotoxicity
Implantation

The sensor pod is a surface device with skin contact and permanent patient contact duration (>30 days) due to repeated/continuous use. The following tests were conducted:

Cytotoxicity
Sensitization
Irritation or Intracutaneous reactivity ●

The Dexcom G6 System applicator needle was defined as an external communicating device

33

with indirect blood path contact and limited patient contact duration (